Placebo News and Research

RSS

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Regular, moderate coffee consumption may help prevent type 2 diabetes

Drinking three to four cups of coffee per day may help to prevent type 2 diabetes according to research highlighted in a session report published by the Institute for Scientific Information on Coffee (ISIC), a not-for-profit organisation devoted to the study and disclosure of science related to coffee and health.

5 Dec 2012

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.

5 Dec 2012

Cabozantinib effectively treats prostate cancer spread to bones

A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.

5 Dec 2012

Linagliptin may reduce brain damage following stroke in type 2 diabetic patients

In a study in mice, scientists at Karolinska Institutet in Sweden have discovered a new potential therapy that may reduce brain damage following stroke in type 2 diabetic patients. The suggested drug is already approved for the treatment of type 2 diabetes. However, the scientists hope that this new results, presented in the scientific journal Diabetes, also opens up the possibility to decrease brain injury after stroke in other patient groups with a high stroke risk.

4 Dec 2012

Antidepressants in normal dosage may positively impact mood and seizure frequency

Epilepsy and depression are common co-morbidities. Concern for the potential of certain antidepressants to induce seizures has led to under-treating depression and anxiety disorders in epilepsy patients. Research presented today at the 66th American Epilepsy Society meeting suggests that antidepressants in normal dosage may have a positive impact on both mood and seizure frequency.

4 Dec 2012

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

3 Dec 2012

Selumetinib plus docetaxel shows KRAS-mutant NSCLC potential

The addition of selumetinib to docetaxel therapy may boost the survival of patients with KRAS-mutant non-small-cell lung cancer, suggest study findings published in The Lancet Oncology.

3 Dec 2012

NAP and SAL injection during pregnancy improve memory, learning tasks in offsprings

Mice with a condition that serves as a laboratory model for Down syndrome perform better on memory and learning tasks as adults if they were treated before birth with neuroprotective peptides, according to researchers at the National Institutes of Health.

30 Nov 2012

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo Pharmaceuticals, Inc. today announced that the Company received a supplement approval from the U.S. Food and Drug Administration (FDA) that removes pregnancy "warnings and precautions" and clarifies information regarding the use of AMITIZA (lubiprostone) by pregnant and/or nursing women. In addition, the FDA expanded the labeling text of the Mechanism of Action section in the prescribing information for AMITIZA.

30 Nov 2012

Topical simvastatin may be answer to nonhealing diabetic wounds

Topical simvastatin significantly accelerates wound healing in mice and may be a good treatment option for diabetic patients with nonhealing wounds, say researchers.

30 Nov 2012

GM1 ganglioside effectively treats patients with Parkinson's disease

Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial, Thomas Jefferson University researchers report in a new study published online November 28 in the Journal of the Neurological Sciences.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

Regorafenib phase III results strongly support use in GIST

Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.

29 Nov 2012

Suvorexant may bring help for people with insomnia

A new drug may bring help for people with insomnia, according to a study published in the November 28, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

29 Nov 2012

Tadalafil may offer therapeutic strategy in patients with Becker muscular dystrophy

Cedars-Sinai Heart Institute researchers have found in an initial clinical trial that a drug typically prescribed for erectile dysfunction or pulmonary hypertension restores blood flow to oxygen-starved muscles in patients with a type of muscular dystrophy that affects males, typically starting in childhood or adolescence.

29 Nov 2012

Placebo News and Research

Sickle cell disease trial completes phase 3 patient enrollment

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Regular, moderate coffee consumption may help prevent type 2 diabetes

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

Cabozantinib effectively treats prostate cancer spread to bones

Linagliptin may reduce brain damage following stroke in type 2 diabetic patients

Antidepressants in normal dosage may positively impact mood and seizure frequency

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Selumetinib plus docetaxel shows KRAS-mutant NSCLC potential

NAP and SAL injection during pregnancy improve memory, learning tasks in offsprings

Sucampo receives supplement approval from FDA for AMITIZA

Topical simvastatin may be answer to nonhealing diabetic wounds

GM1 ganglioside effectively treats patients with Parkinson's disease

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

Regorafenib phase III results strongly support use in GIST

Suvorexant may bring help for people with insomnia

Tadalafil may offer therapeutic strategy in patients with Becker muscular dystrophy

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News